At present, CHB is diagnosed and treated clinically according to the detection of HBsAg, HBV DNA, and ALT, among which ALT, as a sensitive marker of hepatocyte inflammation, has poor specificity, and patients will be affected by drugs, alcohol consumption, fatigue, and other hepatophilic virus infections. This evidence concerns the gene GPT and viral infectious disease.